Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gestational trophoblastic disease/neoplasm: A tertiary referral institution experience with treatment and outcomes
    Meeting Abstract

    Praiss, A.; Liu, Y.; Chiang, S.; Huang, J.; Rizzuto, G.; Weigelt, B.; Jewell, E.; Abu-Rustum, N.; Aghajanian, C.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A comprehensive evaluation of toxicity after radical hysterectomy or trachelectomy and postoperative pelvic intensity-modulated radiation therapy for cervical cancer
    Meeting Abstract

    Miller, M.; Manning-Geist, B.; Dagher, C.; Kim, S.; Kollmeier, M.; Sonoda, Y.; Jewell, E.; Park, K.; Friedman, C.; Leitao, M.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Voices of women with low-grade serous ovarian cancer: Results from a multinational survey
    Meeting Abstract

    Sun, C.; Andrews, N.; Ludemann, J.; Larsen, E.; MacKay, C.; de Fazio, A.; Gaillard, S.; Gourley, C.; Carey, M.; Fader, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update
    Meeting Abstract

    Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; O'Cearbhaill, R.; Bouberhan, S.; Moore, K.; Hou, J.; Hamilton, E.; Yoo, S. Y.; Wang, B.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer
    Meeting Abstract

    Richardson, D.; Iyer, G.; Schmid, A.; Palma, N.; Navarro, W.; Ahnert, J. R.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • nab-Sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer: A phase II, open-label, single-arm, prospective, multicenter study
    Meeting Abstract

    Dockery, L.; Slomovitz, B.; Priebe, A.; Green, A.; Mathews, C.; Musa, F.; Puechl, A.; Birrer, M.; Spirtos, N.; Ding, L.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer
    Meeting Abstract

    Girda, E.; Makker, V.; Marth, C.; Van Gorp, T.; Mirza, M.; Shapira-Frommer, R.; Suttner, L.; Groisberg, R.; Jin, F.; O'Malley, D.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
    Meeting Abstract

    Pothuri, B.; Valabrega, G.; Oaknin, A.; Graybill, W.; Sánchez, A. B.; McCormick, C.; Baurain, J. F.; Tinker, A.; Denys, H.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase II, open-label, multicenter, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically selected advanced or metastatic solid tumors (ARTIST)
    Meeting Abstract

    Aghajanian, C.; Washington, C.; Moore, K.; Krivak, T.; Mathews, C.; Philip, T.; Konecny, G.; Fleming, G.; Martin, N.; Smith, G.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Prognostic value of aggressive histology in surgically-staged, clinically uterine-confined endometrial carcinoma
    Meeting Abstract

    Dagher, C.; Mueller, J.; Abu-Rustum, N.; Sonoda, Y.; Momeni-Boroujeni, A.; Makker, V.; O'Cearbhaill, R.; Alektiar, K.; Leitao, M.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save